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Abstract. Uveal melanoma (UM) is the most common 
primary intraocular malignancy with a very poor prognosis. 
The most frequent chromosome aberration in UM is the 
monosomy of chromosome 3. Previously, we demonstrated 
that ~50% of UMs express type-I receptor for luteinizing 
hormone-releasing hormone (LH-RH-R). The gene encoding 
LH-RH-R is located in chromosome 4 (location: 4q21.2); 
however, the occurrence of  numerical aberrations of chromo-
some 4 have never been studied in UM. In the present study, we 
investigated the abnormalities of chromosome 3 and 4, and the 
possible correlation between them, as well as with LH-RH-R 
expression. Forty-six specimens of UM were obtained after 
enucleation. Numerical aberrations of chromosome 3 and 4 
were studied by fluorescence in situ hybridization (FISH). 
Chromosome 4 was detected in normal biparental disomy only 
in 14 (30%) samples; however, 32 cases (70%) showed more 
than 2 signals/nucleus. Monosomy of chromosome 3 could be 
found in 16 (35%) samples. In 6 specimens (13%), more than 
2 copies of chromosome 3 were found, while normal biparental 
disomy was detected in 24 (52%) samples. Statistical analysis 
indicated a statistically significant (p<0.05) correlation 
between the copy number of chromosome 3 and 4. Moreover, 
moderate difference was revealed in the survival rate of the 
UM patients with various pathological profiles. No correlation 
was found between chromosome aberrations and LH-RH-R 
expression. Our results clearly demonstrate abnormalities in 
chromosome 3 and 4 and the incidence of the monosomy of 
chromosome 3 in human UM. In summary, our results provide 
new incite concerning the genetic background of this tumor. 
Our findings could contribute to a more precise determination 
of the prognosis of human UM and to the development of new 
therapeutic approaches to this malignancy.
Introduction
Uveal melanoma (UM) is the most frequently occurring 
primary intraocular tumor in adults, and is associated with 
significant mortality (1). Several histologic prognostic factors 
have been described for this type of cancer, such as large tumor 
diameter (LTD), location at onset, age at time of diagnosis, 
presence of epitheloid cells and involvement of the ciliary 
body (2). The cause of UM is unknown, but several risk factors 
have been associated with the development of the disease such 
as light irides, uveal naevi, dysplastic naevus syndrome and 
oculodermal melanocytosis. UM most commonly affects 
Caucasian males. Despite the early diagnosis, the mortality 
due to UM has remained relatively unchanged. Specific 
genetic alterations can predict the development of metastasis 
and survival in patients with UM. Monosomy 3 strongly 
predicts metastatic risk and other chromosomal abnormalities, 
also correlated with metastatic diseases (3,4). Approximately 
half of the patients develop metastases, most frequently in the 
liver (5,6). Monosomy 3 correlates with epitheloid histology, 
ciliary body involvement and poor outcome (6). Lack of chro-
mosome 3 has been demonstrated in 5-10% of all the patients, 
and the remaining copy is duplicated (7). Occasionally, 
partial deletions of chromosome 3 have been detected and 
a common region of allelic loss on 3p25 and on 3q24-q26 
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could be defined. Most likely these regions harbor putative 
tumor-suppressor genes, but no specific genes have yet been 
identified (7). Monosomy 3 is present in 50-60% of tumors, 
which is associated with isochromosome 8q and high level of 
8q gain (8). The common region of amplification was found to 
range from 8q24.1 to 8q24.3. A potential metastasis-suppressor 
gene, LZTS1, is located in 8p21 (9). In UM, other recurrent 
chromosome alterations, such as lack of 1p and 16q, have been 
described (10). One of the suggested tumor-suppressor genes, 
APITD1, in the 1p36 region was shown to be negligible for 
survival rate and the common deleted regions on chromosome 1 
were found to range from 1p34.3 to 36.2 (10). Infrequently, 
abnormalities of other chromosomes such as gain of 6p, loss 
of 6q, loss of 9p, loss of chromosome 10, loss of 11q23-q25, 
and gain of chromosomes 7 and 10 have been reported (11). 
UM can be classified into 2 groups based on the status of chro-
mosome 3: class 1 tumors with 2 copies, and class 2 tumors, 
with monosomy of chromosome 3. The characteristics of these 
tumors basically differ; class 1 tumors have been characterized 
by gain of 6p and 8q while class 2 tumors by monosomy 3 and 
gain of entire 8q (12). Class 1 tumors exhibit low aneuploidy, 
and patients rarely have metastases whereas class 2 tumors 
have a higher chance of aneuploidy and patients have a high 
risk to develop metastases (13). Hypothalamic luteinizing 
hormone-releasing hormone (LH-RH) is the primary link 
between the hypothalamus and the pituitary gland in the regu-
lation of gonadal functions and has a pivotal role in vertebrate 
reproduction (14). The effects of LH-RH and its analogs are 
mediated by high-affinity G-protein-coupled receptors located 
on the membranes of the pituitary gonadotrophs and several 
cancer cells (15-17). Tumoral receptors for LH-RH have been 
detected on human breast, prostatic, ovarian, endometrial and 
pancreatic cancers and in human melanomas, non-Hodgkin's 
lymphomas and renal cell carcinomas (14-20). Over the past 
decade, a direct receptor-mediated antiproliferative effect of 
LH-RH-analogs on tumor cells was proposed (14,16,17,19-21). 
The receptors for LH-RH (LH-RH-R) on human tumors can 
also serve as targets for LH-RH analogs linked to various 
cytotoxic agents (15-17,22,23). In our previous study, it was 
demonstrated that a high percentage (47%) of human UMs 
express the type-I receptor for LH-RH (24). The gene encoding 
LH-RH-R is located on chromosome 4q21.2; however, the 
numerical aberrations of chromosome 4 have never been 
studied in UM.
In the present study, we aimed to investigate the copy 
number of chromosome 3, particularly the monosomy of 
chromosome 3 which has been extensively described in the 
aggressive behavior of UM, and chromosome 4 in 46 human 
UM specimens using fluorescence in situ hybridization (FISH). 
Furthermore, chromosome index (CI) and ‘dominant’ cell 
population values for chromosome 3 and 4 were determined. 
Additionally, we analyzed the survival rate of the UM patients 
according to their CI. The correlation between LH-RH-R 
expression and the copy number of chromosome 3 and 4 was 
also investigated.
Materials and methods
Human UM tissues. Specimens of human UM were obtained 
from 46 patients 30-84 years of age at the time of enucleation 
at the Department of Ophthalmology of the University of 
Debrecen, Debrecen, Hungary. Normal lymphocyte samples, 
used as positive controls, were collected at the Department of 
Pathology of the University of Debrecen. Informed consent 
was obtained before enucleation, and the present study 
was performed according to the tenets of the Declaration 
of Helsinki and the Local Institutional Ethics Committee. 
Fresh tumor tissue was obtained within 1 h after enucleation, 
according to a standardized protocol. Briefly, an incision was 
made through the tumor, leaving the optic nerve intact. The 
quantity of tissue obtained (5-8 mm3) depended on the size 
of the tumor. A sample was taken from the side opposite the 
optic nerve and selected portions of the melanoma tissues were 
flash frozen and stored at -80̊C. Conventional histopathologic 
examination was performed on all tumors and the origin of the 
tumor was confirmed. Follow-up data from the time of diag-
nosis until the end of the study were obtained by reviewing the 
charts of the patients (whether we had the availability) and/or 
by contacting their general physicians. The clinicopathological 
data of the 46 patients are summarized in Table I. UM samples 
were divided into 4 groups based on the CI: NN (normal CI3 
and CI4), NP (normal CI3 pathological CI4), PN (pathological 
CI3 and normal CI4) and PP (pathological CI3 and CI4). To 
simplify the evaluation, 2 major groups were also created: 
N (including NN) and P (containing NP, PN and PP).
Touch preparations. The tumor tissues were transferred from 
-80 to -20̊C. The tissue samples were used for touch prepara-
tions, which were obtained by pressing frozen tissue samples 
several times on the surface of a silanized slide. The slides 
were fixed in methanol:acetic acid (3:1), air dried, washed with 
70% acetic acid solution and distilled water, dehydrated with 
70, 80 and 90% ethanol and air dried. The slides were stored 
at -20̊C until further use.
FISH
DNA FISH probes. Numerical aberrations of chromo-
some 3 and 4 were studied by FISH with centromere-specific 
probes (CEP; Chromosome Enumeration DNA FISH 
Probes, vysis, Germany). The probes consisted of chromo-
some 3- or 4-specific tandem-repeat DNA sequences. The CEP 
probes were directly labeled with SpectrumOrange (chromo-
some 3) and SpectrumGreen (chromosome 4) fluorophores. 
The centromeric probes contain 7 µl CEP hybridization buffer, 
1 µl probe and 1 µl distilled water.
FISH hybridization. FISH was carried out according to a 
general protocol with some modifications (25). The slides 
containing the touch preparations were fixed in methanol:acetic 
acid (3:1) at -20̊C, and then incubated in 15 µl 10% pepsin 
in 100 µl 1 M HCl. The slides were washed with 1X PbS 
buffer, and then dehydrated in 70, 85 and 100% alcohol series 
and air dried. DNA FISH probe was added, coverslips were 
applied and sealed to the slide with rubber cement. The slides 
were denatured at 75̊C for 5 min and hybridized overnight at 
42̊C. After hybridization, the slides were washed with 50% 
formamide/2X standard saline citrate (SSC) solution at 42̊C 
for 7 min, and then with 2X SSC solution at 42̊C for 7 min. The 
slides were then counterstained with 4',6-diamidino-2-phenyl-
indole (DAPI) in anti-fade solution (Fig. 1).
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Table I. Clinicopathological characteristics, chromosome index (CI) results and survival data of the 46 uveal melanoma patients.
Sample  Age       Postoperative
ID Gender (years) Type Eye Localization Survival CI3 CI4 days
  1 F 79 ND L C Deceased 1.43 2.72 210
  2 M 76 Spindle L P Alive 2.00 2.65 1,559
  3 F 44 Spindle-b L Inferior temporal: P Alive 2.19 3.39 1,770
  4 F 50 Spindle R Temporal: P Alive 2.41 3.00 1,497
  5 M 76 Spindle R P Deceased (liver) 2.18 3.94 620
  6 F 30 Spindle-A L P Alive 2.17 3.34 1,770
  7 M 66 Epithelioid L Temporal: P Alive 2.04 4.01 333
  8 M 61 Spindle-b L Temporal: P Alive 2.21 2.81 1,505
  9 M 53 ND L Superior temporal: P Alive 2.04 3.94 1,260
10 M 53 Epithelioid R P Alive 1.48 2.79 1,442
11 F 79 Epithelioid R P Dead 2.07 3.43 548
12 M 67 Epithelioid L P Alive 2.10 2.53 1,630
13 F 72 Epithelioid L Temporal: P Deceased (liver) 1.37 5.39 317
14 M 35 Spindle L Superior nasal: P Alive 1.71 2.94 740
15 M 55 Spindle-b L P Alive 2.68 3.03 1,545
16 M 65 Spindle-b R Anterior temporal: P Dead 2.53 1.91 467
17 F 68 Spindle L P Alive 2.07 1.75 1,702
18 M 71 Spindle-b R P Alive 2.28 3.43 1,006
19 M 69 Mixed R Anterior nasal: P Alive 1.37 2.31 958
20 M 64 ND L Temporal: P Deceased (bone) 1.79 2.39 312
21 F 75 Epithelioid L Temporal: P Alive 2.26 3.04 846
22 F 79 ND R C Alive 2.43 2.36 1,442
23 F 75 Mixed L Anterior nasal: P Alive 1.06 1.94 1,902
24 M 70 Mixed R P Alive 1.99 2.06 1,022
25 M 47 Epithelioid L C Deceased (liver) 1.53 2.08 832
26 M 42 Epithelioid R P Alive 2.05 2.48 947
27 M 72 Epithelioid L P Alive 1.97 2.48 932
28 F 68 Epithelioid L Juxtapapillary Alive 1.87 221 965
29 M 72 Epithelioid L P Deceased (liver) 1.88 2.27 29
30 M 64 Spindle L Anterior retinal: P Alive 1.23 2.22 2,021
31 M 42 Epithelioid R P Deceased (orbita) 2.01 2.82 303
32 F 68 Epithelioid R P Deceased (liver/lung) 1.66 2.55 439
33 M 51 Spindle-b L C Alive 0.94 2.14 1,609
34 F 50 Spindle-b R Juxtapapillary Alive 2.22 2.50 1,097
35 M 56 ND L Anterior temporal: P Alive 1.33 2.37 648
36 F 55 Epithelioid L Anterior Alive 2.07 2.04 623
37 F 83 Spindle-A R nasal: P Deceased (liver) 1.40 1.80 261
38 F 63 Spindle-A R C Alive 1.31 2.10 490
39 M 70 Spindle-b R Temporal: P Alive 1.17 2.33 950
40 F 61 Spindle L P Alive 1.88 2.04 740
41 M 70 Epithelioid L P Alive 1.41 1.81 524
42 F 70 Epithelioid R P Alive 1.35 2.26 582
43 F 71 Mix R Anterior Alive 1.76 2.28 559
44 F 52 Mix R Temporal: P Alive 1.93 2.52 560
45 F ND Spindle L C Alive 1.93 2.99 592
46 F 54 Spindle R Anterior temporal: P Alive 1.84 1.91 613
CI3, chromosome index 3; CI4, chromosome index 4; F, female; M, male; ND, no data; L, left; R, right; C, corpus ciliare; P, posterior pole. In 
the survival column, the cause of death (metastasis) is mentioned in brackets.
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Fluorescence microscopy. Slides were evaluated using a fluo-
rescence microscope (Axio Imager z2; zeiss, Oberkochen, 
Germany). Image capture was performed by a monochrome 
charge-coupled device camera attached to the fluorescence 
microscope and ISIS software (MetaSystems, Altlussheim, 
Germany).
FISH analysis. Numerical aberrations of chromosome 3 and 4 
were assessed by analyzing chromosome copy number on the 
basis of 100 relevant tumor cell nuclei. CI values for chromo-
some 3 and 4 were determined for the ratio of the whole FISH 
signal in the sample and the number of nuclei. Chromosome 
loss was stated as <1.75, polysomy was stated as >2.25 chromo-
some copy numbers/nucleus. ‘Dominant’ cell population value 
was determined. A cell population with a certain chromosome 
copy number was considered as ‘dominant’ cell population 
where the cut-off limit was 15% (26).
Statistical analysis. Indices for chromosome 3 and 4 were 
analyzed from the UM samples. The two datasets were evalu-
ated using D'Agostino-Pearson omnibus normality test, and then 
Spearman correlation analysis was performed. Chromosome 
results, receptor findings and clinicopathological data were also 
analyzed. Statistical analysis was carried out with the use of 
GraphPad Prism 6.03 (GraphPad, San Diego, CA, USA).
Survival in the groups was plotted against the postoperative 
days (elapsed until death or the end of the follow-up period), 
according to the Kaplan-Meier method. Differences among the 
groups were investigated by means of Mantel-Cox log-rank 
and Gehan-breslow-wilcoxon tests. Statistical analysis was 
carried out with GraphPad Prism 6.03 software.
Results
Distribution of chromosome 3. based on CI values, mono-
somy of chromosome 3 was found in 16 (35%) samples. In 
6 specimens (13%), >2 copies of chromosome 3 were found. 
Normal biparental disomy was observed in 24 samples (52%). 
In 26 samples one signal/cell/‘dominant’ cell population could 
be detected, whereas in 9 cases, clones containing 3 or more 
chromosome/nucleus were found. In 2 specimens, either loss 
of chromosome or polysomy were observed. Normal distribu-
tion of chromosome 3 was detected in 13 cases. In addition, 
the normal tissue samples contained negligible abnormal cell 
population (<15%) (Table II). Representative distribution of 
chromosome 3 is shown in Fig. 1.
Distribution of chromosome 4. based on the CI values, 
chromosome 4 could be detected in normal biparental 
disomy in 14 samples (30%), while 32 cases (70%) showed 
>2 signals/nucleus. In 8 samples one signal/cell/‘dominant’ 
cell population was observed, whereas in 41 cases, clones 
containing 3 or more chromosome/nucleus were found. In 
6 specimens either loss of chromosome or polysomy was 
observed. Normal distribution of chromosome 4 was detected 
only in 3 cases (Table III). Representative distribution of chro-
mosome 4 is shown in Fig. 1.
Statistical results. According to the statistical analysis, 
there was (Spearman r=0.42; 0.139-0.639; CI, 0.95%) a 
statistically significant (p<0.05) correlation between the 
copy number of chromosome 3 and 4 (Fig. 2). CI values 
for chromosomes 3 and 4 were determined for the samples 
and were considered to be normal (N, 1.75-2.25) or patho-
logical (P, <1.75 or >2.25). Comparing the survival rate of the 
4 groups (NN, NP, PN and PP), an obvious difference was 
revealed, however statistically significant differences could 
not be shown (p=0.38 for the Mantel-Cox test, and p=0.43 for 
the Gehan-breslow-wilcoxon test). Even the 2 major groups 
(N and P) were not found to be significantly different (p=0.12 
by both the Mantel-Cox and Gehan-breslow-wilcoxon tests), 
in spite of the considerable difference between their survival 
curves (Fig. 3). The correlation of aberrations in chromo-
some 3 and 4 with LH-RH-R findings was also investigated 
in 17 UM samples where receptor data were available (24). No 
significant correlation was found among chromosome expres-
sion and LH-RH-R incidence and binding characteristics. 
Furthermore based on our findings and the clinicopathological 
data, no correlation was observed between clinical outcome 
and chromosome 3 and 4 status (data not shown).
Figure 1. Representative image of FISH analysis in human uveal melanoma. Nuclei were stained with blue fluorescent DAPI. Specific signals for chromo-
some 3 are indicated in red; chromosome 4-specific signals are indicated in green.
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 ‘Dominant’ cell ‘Dominant’ cell
 population 1 population 2
Sample -------------------------------- ---------------------------------
ID Signals/cell % Signals/cell % CI
33 1 85   0.94
23 1 94   1.06
39 1 78   1.17
30 1 77   1.23
38 1 69   1.31
35 1 71   1.33
42 1 66   1.35
13 1 65   1.37
19 1 64   1.37
37 1 62   1.40
41 1 62   1.41
  1 1 62   1.43
10 1 60   1.48
25 1 52   1.53
32 1 39   1.66
14 1 49   1.71
43 1 25   1.76
20 1 34   1.79
46 1 23   1.84
28 1 21   1.87
29 1 19   1.88
40 1 17   1.88
44 Normal 1.93
45 Normal 1.93
27 1 21   1.97
24 Normal 1.99
  2 1 35   2.00
31 Normal 2.01
  7 Normal 2.04




36 3 17   2.07
12 1 24 3 18 2.10
  6 Normal 2.17
  5 Normal 2.18
  3 Normal 2.19
  8 Normal 2.21
34 3 21   2.22
21 3 19   2.26
18 1 42 ≥4 27 2.28
  4   3 18 2.41
22 3 20   2.43
16 3 18 ≥4 18 2.53
15 3 29 ≥4 22 2.68
A cell population with a certain chromosome copy number was con-
sidered as ‘dominant’ cell population where the cut-off limit was 15%. 
The samples are listed according to their chromosome index (CI).




 ‘Dominant’ cell ‘Dominant’ cell
 population 1 population 2
Sample -------------------------------- ---------------------------------
ID Signals/cell % Signals/cell % CI
17 1 22   1.75
37 1 44 3 24 1.80
41 1 39 3 20 1.81
16 1 15   1.91
46 1 26 3 17 1.91
23 Normal 1.94
36 1 23 3 24 2.04
40 1 30 3 32 2.04
24 Normal 2.06
25 Normal 2.08
38 1 20 3 28 2.10
33 3 21   2.14
28 1 16 3 21 2.21
30 3 26   2.22
42 3 36   2.26
29 3 26   2.27
43 3 38   2.28
19 3 15   2.31
39 3 44   2.33
22 3 20   2.36
35 3 32   2.37
20 3 18   2.39
26   ≥4 18 2.48
27 3 25 2.48
34 3 37 2.50
44 3 34 2.52
12 3 20 2.53
32 3 42 2.55
  2 3 16 2.65
  1 ≥4 30 2.72
10 3 25 ≥4 22 2.79
  8 3 45   2.81
31 3 48   2.82
14 3 19 ≥4 33 2.94
45 3 58 ≥4 21 2.99
  4 3 26 ≥4 26 3.00
15 3 19 ≥4 39 3.03
21 3 79   3.04
  6 3 28 ≥4 42 3.34
  3 3 27 ≥4 43 3.39
11 3 28 ≥4 47 3.43
18 3 15 ≥4 24 3.43
  5 3 19 ≥4 72 3.94
  9   ≥4 81 3.94
  7 3 22 ≥4 67 4.01
13   ≥4 91 5.39
A cell population with a certain chromosome copy number was con-
sidered as ‘dominant’ cell population where the cut-off limit was 15%. 
The samples are listed according to their chromosome index (CI).
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Discussion
Uveal melanoma (UM) is the most common form of primary 
ocular cancer in adults, with a mortality rate of 50% at 
10-15 years after detection of the disease (27). Clinical treat-
ment for the disease includes photocoagulation, radiotherapy, 
local tumor incision and eye removal. However, none of these 
treatments improves the survival rate noticeably (28). Adjuvant 
systemic therapy is mainly used in patients with high-risk of 
metastasis or in patients already presenting with metastasis, 
but the response rates to classical chemotherapeutic agents 
remain low (29). we previously demonstrated that LH-RH-R is 
expressed in approximately half (47%) of human UMs (24). The 
effects of LH-RH and its analogs are mediated by high-affinity 
G-protein-coupled receptors for LH-RH located on the 
membranes of the pituitary gonadotrophs and different human 
types of cancers (16,17,19-21). The presence of LH-RH-R in 
various types of cancers and cancer cell lines originating 
from organs other than those of the reproductive system has 
been shown in various studies (14,16-19,21,30). both agonists 
and antagonists of LH-RH may serve as potential therapeutic 
agents, acting directly on the target cancer cells (16,17,30-32). 
LH-RH agonists inhibit the gonadotropin secretion after 
continuous exposure (31). In contrast, antagonists of LH-RH 
produce a competitive blockade of LH-RH-R leading to an 
immediate cessation of the secretion of gonadotropins and 
sex steroids, reducing the time of the onset of therapeutic 
effects compared to the agonists (33). Agonistic analogs, 
such as triptorelin, leuprolelin, goserelin and buserelin are 
extensively applied in gynecology and oncology (14,16-18,30). 
Potent antagonists of LH-RH, such as cetrorelix, ganirelix, 
abarelix and degarelix, have also been developed and are now 
available for clinical use (14,16-18,30,33). The receptors for 
LH-RH on human tumors also serve as targets for LH-RH 
analogs linked to cytotoxic agents (15-17,19,23,34). In the 
analog AN-152 (AEzS-108) doxorubicin (DOX) is covalently 
linked to the LH-RH agonist D-Lys6-LH-RH, that binds to the 
receptors present on the surface of breast, prostatic, ovarian 
and other cancer cells (15-17,23,34). This analog has been 
extensively investigated in a large number of experimental 
studies (14-19,23,30,34), and also tested clinically in ovarian, 
endometrial, prostatic and bladder cancer. It is in clinical 
phase III trials on endometrial cancer (35). Generally, the 
genetic background of different cancers is extensively inves-
tigated. For example, aberrations of chromosome 4 have 
been demonstrated in cervical cancer, small cell lung cancer, 
glioblastoma and chronic lymphocytic leukemia (36-39). 
Chromosome 4 hyperploidy is the most prominent alteration 
found in barrett's metaplasia and 89% of the patients display 
this aberration (40). Notably, the gene encoding LH-RH-R is 
located on chromosome 4q21.2. The numerical aberrations of 
chromosome 4 have never been studied in UM.
It was reported that monosomy 3 strongly predicts meta-
static risk and other chromosomal abnormalities correlate with 
metastatic disease (3,4). Monosomy 3 in choroidal melanoma 
is a significant predictor of metastasis-related death and has 
been associated with a 70% decrease in 5-year survival. 
Infrequently, abnormalities of other chromosomes such as 
losses of 1p, 6q, 9p, 10, 11q23-q25, and gain of chromosomes 
6p, 7, 8q and 10 have been reported (3,11). Recently, several 
potential genes were proposed in UM, such as GNAQ, DDEF1, 
NBS1, HDM2, BCL-2 and CCND1; however, a significant 
role for most of these genes must be further investigated in 
tumorigenesis and progression towards metastasis must be 
confirmed (41,42).
In the present study, one of our aims was to investigate 
the copy number of chromosome 3 due to the fact that it has 
been implicated in the aggressive behavior of UM. More 
importantly, copy number of chromosome 4 was also studied 
in the same human UM specimens using fluorescence in situ 
hybridization (FISH). The correlation between LH-RH-R 
Figure 3. Kaplan-Meier survival curves of patients with uveal melanoma. 
(A) NN (normal CI3 and CI4), NP (normal CI3 pathological CI4), PN 
(pathological CI3 and normal CI4) and PP (pathological CI3 and CI4) status 
(p=0.38 for the Mantel-Cox and p=0.43 for the Gehan-breslow-wilcoxon 
tests). (b) N (including NN) and P (containing NP, PN and PP) status (p=0.12 
for both the Mantel-Cox and Gehan-breslow-wilcoxon tests).
Figure 2. Correlation between the copy number of chromosome 3 and 4 in 
46 human uveal melanoma specimens. A significant (p=0.0036) correlation 
was noted between the copy number of chromosome 3 and 4 (Spearman 
r=0.42; 0.139-0.639; CI, 0.95%).
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expression, clinicopathological findings and numerical aberra-
tions of chromosome 3 and 4 was similarly analyzed.
FISH can detect chromosomal alterations that are consis-
tent with a diagnosis of neoplasia. Several studies have shown 
that FISH has significantly higher sensitivity for the detection 
of tumor cells than conventional cytology (43-45). FISH is 
also able to detect various types of cytogenetic alterations 
including aneusomy, duplication, amplification, deletion and 
translocation (8). In general, 3 basic types of DNA probes are 
used: centromeric (chromosome enumeration probes), whole 
chromosome (whole chromosome paints) and locus-specific 
probes (46).
We demonstrated in the present study, for the first time, 
that chromosome 4 is present in an abnormal copy number 
in the majority of UMs. based on the chromosome index 
(CI) values, in 70% of samples of chromosome 4, more than 
2 signals/nucleus were detected while the normal 2 copies 
were found only in 30% of the cases. The monosomy of chro-
mosome 3 was detected in 35% of the samples while in 13% 
of the cases polysomy was observed. Our results are somewhat 
different from previous studies concerning the frequency of 
the monosomy of chromosome 3 (50%) (47-50). This slight 
difference may be partially explained by the possibly diverse 
genetic background of the Hungarian population.
In case of chromosome 3, based on ‘dominant’ cell popu-
lation values, one signal/cell/‘dominant’ cell population was 
observed in 26 samples whereas we found clones containing 3 
or more chromosomes/nucleus in 9 cases. In 2 specimens 
either loss of the chromosome or polysomy was observed.
In the case of chromosome 4, one signal/cell/‘dominant’ was 
observed in 8 samples whereas in 41 cases clones containing 3 
or more chromosomes/nucleus were detected. In 6 specimens 
either loss of the chromosome or polysomy was observed.
According to our statistical analysis, there is a moderate, 
statistically significant correlation between the copy numbers 
of chromosome 3 and 4, but no correlation was found with 
LH-RH-R expression and chromosome aberrations.
we also determined the survival rate of the UM patients 
according to their CI. Comparison of the survival rate of the 
4 groups (NN, NP, PN and PP) and the 2 major groups (N 
and P), a moderate difference was revealed, although statisti-
cally significant differences could not be proven in spite of 
the considerable difference between their survival curves. 
As mentioned above, the diverse genetic background of the 
Hungarian population as well as the limited number of human 
UM specimens may have contributed to the limitation of the 
present study. Our research is in the early phase of the investiga-
tion of chromosome 4 status; therefore, multivariate statistical 
analysis may not be a proper statistical test at this moment. 
However, investigation of a larger population may be important 
which may indeed require a more powerful statistical test, such 
as multivariate statistical analysis. In conclusion, our results 
provide new informations concerning the genetic background 
of UM and may lead to a more precise prognosis and novel 
therapeutic approaches for cancer of the eye.
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